ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-OR36

Hospital Health Care Costs Following Incident CKD in Japan, Sweden, and the United States

Session Information

Category: CKD (Non-Dialysis)

  • 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Tangri, Navdeep, University of Manitoba Max Rady College of Medicine, Winnipeg, Manitoba, Canada
  • Svensson, Maria K., Uppsala Universitet, Uppsala, Sweden
  • Sofue, Tadashi, Kagawa Daigaku, Takamatsu, Kagawa, Japan
  • Bodegard, Johan, AstraZeneca, Gothenburg, Sweden
  • Adamsson Eryd, Samuel, AstraZeneca, Gothenburg, Sweden
  • Thuresson, Marcus, Statisticon AB, Uppsala, Sweden
  • Gustafsson, Stefan, Sence Research AB, Uppsala, Sweden

Chronic kidney disease (CKD) affects an estimated 10% of the global population. It is associated with cardiorenal complications (e.g. end stage kidney disease and heart failure [HF]), premature mortality, and high healthcare burden and costs. Here we assess hospital healthcare costs following incident CKD.


This study uses secondary data from electronic health records or claims data sources from Japan, Sweden and the US. Adult patients with incident CKD (defined as having either: two estimated glomerular filtration rate [eGFR] measurements ≥ 90 days apart of ≤ 60 mL/min/1.73 m2 or an eGFR measurement ≤ 60 mL/min/1.73 m2 followed by a CKD diagnosis) were identified during 2016–2023. Cumulative costs per patient for hospitalizations associated with a main diagnosis of HF, CKD, myocardial infarction (MI), stroke or peripheral artery disease (PAD) were summarized for up to 5 years after index (date of second eGFR measurement or CKD diagnosis).


Overall, 549 884 patients were included (Japan, 74 285; Sweden, 76 133; US, 399 466). In Japan, Sweden and the US, respectively: median ages were 81, 78 and 74 years; 54%, 48% and 37% were males; and across countries the majority (68%) of patients did not have type 2 diabetes. Median eGFR measurements were similar across countries. Hospital healthcare costs associated with cardiorenal events (CKD and HF) were high (Figure). Atherosclerotic cardiovascular disease (MI, stroke and PAD) contributed less to hospital healthcare costs.


Hospital healthcare costs were high and largely driven by cardiorenal events (CKD and HF) among patients with incident CKD. This was consistent across all three countries, despite differences in healthcare systems.


  • Commercial Support – AstraZeneca